Highlights ARS Pharmaceuticals, Inc.

Equities

SPRY

US82835W1080

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-11 pm EDT			5-day change	1st Jan Change
11.11 ^USD	+6.21%		+22.22%	+102.74%

Jul. 11	Ars Pharmaceuticals Insider Sold Shares Worth $961,725, According to a Recent SEC Filing	MT
Jul. 11	Ars Pharmaceuticals Insider Sold Shares Worth $961,725, According to a Recent SEC Filing	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ARS Pharmaceuticals' Adrenaline Nasal Spray Receives EMA Committee's Positive Opinion	Jun. 28	MT
EU regulator recommends approval for ARS pharma's nasal spray alternative to EpiPen	Jun. 28	RE
ARS Pharmaceuticals, Inc. Announces EURneffy (Adrenaline Nasal Spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (Anaphylaxis)	Jun. 28	CI
ARS Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
ARS Pharmaceuticals, Inc. Submits Response for Neffy (Epinephrine Nasal Spray) Marketing Authorization Application to EMA's Chmp	Apr. 30	CI
Ars Pharmaceuticals, Inc. Enters Exclusive License and Distribution Agreement with CSL Seqirus for Commercialization of Neffy in Australia and New Zealand	Apr. 30	CI
ARS Pharmaceuticals Files Response to FDA Complete Response Letter For Neffy	Apr. 03	MT
ARS Pharmaceuticals, Inc. Submits Response to FDA Complete Response Letter for Neffy® (Epinephrine Nasal Spray)	Apr. 03	CI
ARS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
North American Morning Briefing : Stock Futures -2-	Mar. 06	DJ
ARS Pharmaceuticals Announces neffy Meets Primary Endpoints and Shows Rapid Symptom Control in Phase 2 Urticaria Clinical Study	Feb. 26	CI
ARS Pharmaceuticals, Inc. Announces Favorable Topline Results from Repeat Dosing Study of neffy (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA?s Complete Response Letter	Feb. 20	CI
ARS Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Ars Pharmaceuticals, Inc. Announces Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical Immunology	23-10-03	CI
Top Stories at Midday: Instacart Loses Ground; Ford Averts Canadian Strike; Stellantis Starts Furloughs; Apple, Goldman Explore Trading App	23-09-20	MT
ARS Pharmaceuticals' CRL Announcement a 'Major Blow' to Neffy Approval, Wedbush Says	23-09-20	MT
Rate Hike Pause Hopes Boost Exchange-Traded Funds, Equity Futures Premarket Wednesday	23-09-20	MT
ARS Pharmaceuticals Shares Sink Premarket as FDA Rejects Neffy Spray	23-09-20	DJ
US FDA declines to approve first nasal spray equivalent of EpiPen	23-09-19	RE
ARS Pharmaceuticals, Inc. Announces FDA Issues Complete Response Letter for neffy(R) (epinephrine nasal spray) New Drug Application with Request for Additional Study	23-09-19	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights ARS Pharmaceuticals, Inc.

Equities

SPRY

US82835W1080

Highlights

Filters